Binetti R, Costamagna F M, Marcello I
Inventario Nazionale delle Sostanze Chimiche, Dipartimento Ambiente e Connessa Prevenzione Primaria, Istituto Superiore di Sanità, Rome, Italy.
J Exp Clin Cancer Res. 2003 Dec;22(4):651-72.
The aim of this review is to support the medical staff engaged in tumor therapy with the carcinogenicity, mutagenicity, developmental toxicity classification of a large number of chemiotherapic drugs by national and international Agencies; it also gives their rationale and the few cases for which the classification varies among, for example, the European Union and the United States of America. A large list of such drugs, producers, commercial names, CAS numbers and chemical names is reported. This list is subject to changes for the quick development in this field: many drugs are retired and many more are introduced in clinical practice. The list is updated to the summer 2003 and retains many drugs which have more than one use or have limited use. The protection of the medical personnel using antitumor chemiotherapics can need retrospective epidemiological investigations and obsolete drugs are of importance for some of the past exposures.
本综述的目的是为从事肿瘤治疗的医务人员提供支持，介绍国家和国际机构对大量化疗药物的致癌性、致突变性、发育毒性分类；还给出了分类依据以及例如在欧盟和美利坚合众国之间分类存在差异的少数情况。报告了此类药物、生产商、商品名、CAS编号和化学名的一大列表。由于该领域的快速发展，此列表可能会发生变化：许多药物已停用，更多药物被引入临床实践。该列表更新至2003年夏季，保留了许多有多种用途或使用有限的药物。使用抗肿瘤化疗药物的医务人员的防护可能需要进行回顾性流行病学调查，而一些过去的暴露情况中，过时的药物很重要。
